Developing Solutions for Unmet Clinical Needs
Veracyte is advancing the development of diagnostics for thyroid nodules, difficult-to-diagnose lung diseases, and lung cancer — all of which have high rates of ambiguous diagnostic results using current technologies. We aim to develop products that enable doctors to make better and more efficient treatment decisions that improve patient care and provide cost savings to the healthcare system.
In late 2010, Veracyte successfully launched the Gene Expression Classifier as part of its Afirma Thyroid FNA Analysis for thyroid nodule assessment. Veracyte is embarking on additional genomic tests that will be incorporated into our comprehensive Afirma Thyroid FNA Analysis, further improving clinical patient management.
The lung program is in early biomarker discovery. Similar to our thyroid program, we are employing a whole-genome approach to discovery, rigorous analytical methods development, and stringent clinical validation trials that demonstrate the test performance in the broad patient population.